Recent studies have focused on the intersection of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and dopaminergic communication. While GCGR activators are widely employed for addressing type 2 T2DM, their emerging consequences on motivation circuits, specifically influenced by DA networks, are receiving considerable interest. Th